Genprex (NASDAQ: GNPX) Completes Another Milestone

Genprex (NASDAQ: GNPX) Completes Another Milestone

Genprex (GNPX) Completes Scale-up of REQORSA™ Manufacturing at a CDMO

Good day everyone,

We are continuing our coverage of Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company involved in developing various approaches to treating cancer and diabetes.

Current price $4.47 per share

GNPX opened Tuesday’s session at $4.10 per share, hitting a high for the day of $5.45. Since our initial alert Monday at $3.50/share, GNPX has gained 27.7%.

On Monday we pointed out that Genprex has some things in common with our last week’s alert Vuzix. Both have been trending and have broken through their 50 DMA and 200 DMA in a bullish manner. Their Simple Moving Averages, at all levels, are green. Both companies have similar share structures and significant levels of insider and institutional ownership.

We alerted Vuzix on December 15, and in only six trading sessions VUZI shares went from $4.84/share to yesterday’s close of $10.60, gaining 119%.

Genprex keeps delivering good news:

Genprex Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials for Lung Cancer

We told you that the company was moving its REQORSA production from the lab it was created in, to a commercial Contract Development and Manufacturing Organization.

For the first time, REQORSA was manufactured in a scaled-up clinical production in accordance with the current Good Manufacturing Practices required by the FDA in advance of commercial approval of a drug product.

The new level of production will facilitate the REQORSA need for the Acclaim-1 and Acclaim-2 clinical trials that combine REQORSA with Tagrisso® (AstraZeneca) and with Keytruda® (Merck & Co., Inc.).

Consider this statement by Michael Redman, Executive Vice President and Chief Operating Officer of Genprex. “This achievement positions Genprex with the manufacturing capability for potential future commercialization in the rapidly growing lung cancer therapeutics market, which is projected to grow to $26.3 billion by 2023.”

These two clinical trials have the potential to confirm REQORSA and ONCOPREX as viable cancer fighting therapies. Beyond that goal, if either Acclaim trial is successful in increasing the efficacy of Tagrisso or Keytruda, there is the potential for an exit to either Astra Zeneca (market cap $128B) or Merck (market cap $200B).

It’s crucial to repeat these considerations for GNPX interest:

Low float (est.) 32.48M shares

Trending shares (see chart)

Proprietary technology and recent milestones

Current price is still 36% off 52-week high

Share price has broken through DMA levels in a bullish manner

No other company has technology like GNPX.

The M.D. Anderson Cancer Center is a respected oncology research center, known all over the world. When they license a discovery (REQORSA, ONCOPREX to Genprex), there is an almost certain chance it’s viable science with market potential.

We believe the success of GNPX is still in its infancy and there are exciting milestones to come in the near term. Wouldn’t it be great if this is the one that cures cancer?

Stay safe and be ready for a possible new report after the long Holiday weekend,
The Traders News Group


Privacy Policy and Disclaimer
Your Consent
By using our site, you consent to our online privacy policy and disclaimer.
Do we disclose any information to outside parties?
We do not sell your information to anyone. Please see our cookie policy below.
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, the small acp stock reports you requested, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
Online Privacy Policy Policy
This online privacy policy applies to information collected through our website and social media platforms.
Contacting Us
If there are any questions regarding this privacy policy or disclaimer you may contact us using the information below.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. TNS LLC’s sister company (scs llc) has been compensated ten thousand dollars cash via bank wire by legends media llc for this week’s updated coverage of gnpx and twenty three thousand three hundred and thirty three dollars via bank wire by legends media llc for our recent coverage of vuzi. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.